Imagin Medical Inc. IMEXF Archives - Page 3 of 6

MondayApr 26, 2021 12:10 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Advancing i/Blue(TM) Imaging Solution

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is advancing its proprietary and patented i/Blue(TM) Imaging System. Imagin’s goal is to reduce the cost of treatment for patients with bladder cancer while also improving their chances of survival. Its solution “advances the blue light procedure by allowing surgeons to see the bladder wall under both white and blue light simultaneously in side-by-side presentation, whereas existing systems require surgeons to toggle back and forth between white and blue during the course of the procedure.” According to an article detailing this matter, the existing systems have proven disadvantageous because they…

ThursdayApr 15, 2021 11:11 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Targets $400M Slice of Massive Global Endoscopy Market

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has hailed its first product, the i/Blue(TM) Imaging System, as a breakthrough technology that will advance the accuracy and efficiency of bladder cancer detection and removal, thus helping it capture some market share. The global endoscopy market is valued at $46 billion, of which Imagin is positioned to target $400 million with its bladder cancer detection product. An article detailing this reads, “The company’s patented ultrasensitive imaging product based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.” According to…

ThursdayApr 08, 2021 1:47 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Creates Win-Win Solution for Hospitals, Patients

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a solution set to lower the cost of treating bladder cancer and also help hospitals save money. As a result, Imagin will create a win-win situation for every party involved. The i/Blue(TM) Imaging System, Imagin’s proprietary solution, achieves this in two ways. “By displaying the blue light image that shows the highlighted cancer cells alongside the white light image that shows the full landscape of the bladder, the i/Blue Imaging System will provide surgeons with improved visualization to locate and resect tumors. The overall result is a reduction…

WednesdayApr 07, 2021 12:02 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Innovative Imaging Technology Overcoming Challenges Involving Bladder Cancer Visualization

90% of the cystoscopies performed on bladder cancer patients use white light, which cannot always detect cancer margins or tumors that lie flat against the bladder wall. The American Urology Association recommends blue light for cystoscopic procedures involving bladder cancer. Imagin Medical’s i/Blue Imaging System(TM) provides the simultaneous, side-by-side display of white light and blue light images, making it easier to visualize cancer margins and flat tumors, potentially resulting in lower recurrence rates The company is has transitioned to the manufacturing stage of the i/Blue System with their contract manufacturer, Lighthouse Imaging Bladder cancer is the sixth most prevalent cancer…

FridayMar 26, 2021 12:58 pm

High Bladder Cancer Treatment Cost Finds Help with Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Technology

Bladder cancer is the 6th most prevalent cancer in the United States and a problem worldwide Bladder cancer is more common in men than women at a 4:1 ratio Bladder cancer treatment has the highest cost per patient over the course of a lifetime because of its greater than 50% recurrence rate Surgeons, including urologists at the University of Washington, have adopted a solution that uses blue light and a contrast agent to better visualize bladder tumors and has been shown to be more successful and reduce costs Imagin Medical has taken this solution one step further by developing the…

FridayMar 26, 2021 12:24 pm

QualityStocksNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Technology Rectifies Cystoscopy Limitations

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed proprietary technology that solves the issues associated with existing cystoscopies. “White light images show the full landscape of the bladder but do not effectively highlight cancer,” reads an article about the benefits of the i/Blue Imaging(TM) System, Imagin Medical’s proprietary technology. “A promising new modality, blue light cystoscopy, uses blue-filtered white light to detect flat tumors and cancerous cells not seen with white light. However, surgeons can’t operate using blue light images. The blue images aren’t in real-time, orientation in the bladder is easily lost, and the surgeon…

TuesdayMar 23, 2021 2:14 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Reports Manufacturing Progress for Innovative Bladder Cancer Imaging System

Imagin Medical believes the i/Blue System can revolutionize the current standard of care for bladder cancer patients by improving cancer visualization for removal, and potentially lowering recurrence rates Imagin Medical is leveraging the significant expertise in optics, electronics, software, and mechanical design of FDA-registered contract manufacturer, Lighthouse Imaging, to implement the final stage of the i/Blue(TM) Imaging System Lighthouse’s manufacturing program remains on track for product commercialization in 2022 Surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) is continuing progress with the commercial-stage manufacturing of its patented i/Blue Imaging System, an innovative technology that the company believes will revolutionize…

FridayMar 19, 2021 12:40 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Remains on Schedule to bring in Bladder Cancer Imaging System to Market

Bladder cancer is the fourth most common cancer in men andexpected to cause more than 17,000 deaths in the United States this year Imagin Medical is advancing its patented bladder cancer visualization technology toward commercialization and FDA approval, expecting the technology to revolutionize blue light cystoscopy procedures and improve patient outcomes in the process Imagin is funding its efforts with $2.165 million raised towards its convertible note offering Rollout of the company’s manufacturing process was delayed about nine months as a result of the COVID-19 pandemic.but Imagin and its production partner remain on its revised schedule The company expects to…

WednesdayMar 17, 2021 2:00 pm

Imagin Medical (CSE: IME) (OTCQB: IMEXF), With Their Advanced i/Blue(TM) Imaging System, Closes Second Tranche of Convertible Note Offering

Imagin Medical is a surgical company focused on developing its i/Blue(TM) Imaging System, employing patented ultrasensitive imaging technology The i/Blue(TM) Imaging System is system compatible; system attaches to most endoscopes The company recently closed the second tranche for the amount of US$1,415,500 of the Convertible Note offering Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive surgical procedures. Imagin Medical is run by an experienced management team that is preparing their i/Blue(TM) Imaging System for the industry. An FDA approval process is underway. The company’s patented ultrasensitive…

TuesdayMar 16, 2021 12:44 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces Continued Manufacturing Progress

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Prior to selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System(TM) in October 2020, Imagin received multiple fully functional feasibility units from its original design partner, Optel Inc. Lighthouse’s development program has since focused on further refining the design to support Imagin’s submissions to the U.S. Food and Drug Administration, as well as to ensure final device performance, compliance with all…

Site Search

Company Search

Tag: Imagin Medical Inc. IMEXF